InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,306.04
(
0.02%
)
US TECH 100
18,387.60
(
0.38%
)
Dow Jones
38,852.86
(
-0.55%
)
Brent Oil
84.19
(
-0.17%
)
Bitcoin
68,449.03
(
0.23%
)
Post# of 251952
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119702
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 133475

Wednesday, 12/21/2011 10:36:22 AM

Wednesday, December 21, 2011 10:36:22 AM

Post# of 251952
Teva forecasts $3.8B of worldwide Copaxone sales in 2012, which is a slight decline from the approximately $4.08B annualized run rate in 3Q11. Increased competition from Gilenya and forced price reductions in Europe are presumably the impetus for the tepid forecast.

Teva hasn’t issued a 2012 forecast for Copaxone sales in the US, specifically. In 3Q11, US Copaxone sales were $752M (a $3B annualized run rate) and they comprised 74% of worldwide sales. If, for the sake of discussion, we assume that this 74% figure will hold in 2012, Teva is forecasting US Copaxone sales of $2.8B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up